NYSEAMERICAN:IBIO

iBio Stock Forecast, Price & News

$1.47

-0.07 (-4.55 %)

(As of 01/15/2021 08:00 PM ET)

Add

Compare

Today's Range

$1.46

Now: $1.47▼

$1.58

50-Day Range

$1.05

MA: $1.33▼

$2.05

52-Week Range

$0.23

Now: $1.47▼

$7.45

Volume171,429 shs

Average Volume19.59 million shs

Market Capitalization$267.70 million

P/E RatioN/A

Dividend YieldN/A

Beta-5.81

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.

Overall MarketRank^™

1.34 out of 5 stars

Medical Sector

549th out of 1,556 stocks

Pharmaceutical Preparations Industry

278th out of 638 stocks

3.5 Analyst's Opinion

Consensus Rating
iBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.00, iBio has a forecasted upside of 36.1% from its current price of $1.47.
Amount of Analyst Coverage
iBio has only been the subject of 1 research reports in the past 90 days.

3.2 Community Rank

Outperform Votes
iBio has received 164 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
iBio has received 96 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
iBio has received 63.08% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about iBio and other stocks. Vote “Outperform” if you believe IBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
iBio does not currently pay a dividend.
Dividend Growth
iBio does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, iBio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.00% of the stock of iBio is held by insiders.
Percentage Held by Institutions
Only 8.78% of the stock of iBio is held by institutions.

0.0 Earnings and Valuation

Price to Book Value per Share Ratio
iBio has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:IBIO

Previous SymbolNASDAQ:IBIO

CUSIPN/A

CIK1420720

Webwww.ibioinc.com

Phone+1-302-3550650

Employees43

Debt

Debt-to-Equity Ratio0.40

Current Ratio16.84

Quick Ratio16.67

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.64 million

Price / Sales163.23

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.48 per share

Price / Book3.06

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-16,440,000.00

Net Margins-1,005.62%

Return on Equity-55.71%

Return on Assets-26.91%

Miscellaneous

Outstanding Shares182,108,000

Market Cap$267.70 million

Next Earnings Date2/12/2021 (Estimated)

OptionableNot Optionable

$1.47

-0.07 (-4.55 %)

(As of 01/15/2021 08:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

iBio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Is iBio a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" iBio stock.
View analyst ratings for iBio or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than iBio?

Wall Street analysts have given iBio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but iBio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is iBio's next earnings date?

iBio is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for iBio.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) posted its quarterly earnings results on Monday, November, 16th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.03. The biotechnology company earned $0.41 million during the quarter. iBio had a negative return on equity of 55.71% and a negative net margin of 1,005.62%.
View iBio's earnings history.

When did iBio's stock split? How did iBio's stock split work?

Shares of iBio reverse split before market open on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 8th 2018. An investor that had 100 shares of iBio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

1 brokerages have issued 1 year price objectives for iBio's shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate iBio's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 36.1% from the stock's current price.
View analysts' price targets for iBio or view Wall Street analyst' top-rated stocks.

Who are some of iBio's key competitors?

Some companies that are related to iBio include Annexon (ANNX), Zogenix (ZGNX), Athenex (ATNX), Indivior (INVVY), Organogenesis (ORGO), Akero Therapeutics (AKRO), Radius Health (RDUS), Syndax Pharmaceuticals (SNDX), Tocagen (TOCA), Morphic (MORF), Enanta Pharmaceuticals (ENTA), Protagonist Therapeutics (PTGX), Pliant Therapeutics (PLRX), Vectura Group (VEGPF) and Cara Therapeutics (CARA).
View all of IBIO's competitors.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia (NOK) and Moderna (MRNA).

Who are iBio's key executives?

iBio's management team includes the following people:

Mr. Thomas F. Isett III, CEO & Chairman (Age 55, Pay $1.03M)
Mr. Robert L. Erwin, Pres (Age 67, Pay $291.75k)
Mr. Robert B. Kay, Interim Sec., Interim Treasurer & Director (Age 80, Pay $324.69k)
Mr. John Delta, Principal Accounting Officer & Principal Financial Officer (Age 58)
Mr. Randy Joe Maddux, Chief Operating Officer (Age 59)
Dr. Renato Lobo, Chief Medical Officer
Dr. R. Barry Holtz, Pres of iBio CDMO
Carlos Picosse, Chief Exec. Officer of IBio Brazil

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

How do I buy shares of iBio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $1.47.

How big of a company is iBio?

iBio has a market capitalization of $267.70 million and generates $1.64 million in revenue each year. iBio employs 43 workers across the globe.

What is iBio's official website?

The official website for iBio is www.ibioinc.com.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here